anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Essentially pure soluble human CD7 proteins are disclosed. Anti-CD7 antibodies are disclosed. Anti-CD7 antisense compounds are disclosed. Pharmaceutical compositions which comprise active ingredients selected from the group consisting of: soluble human CD7 protein, anti-CD7 antibodies and anti-CD7 antisense compounds are disclosed. Transgenic animals that comprise human CD7 are disclosed. Methods of purifying human immunodeficiency virus and methods of diagnosing and treating individuals infected with human immunodeficiency virus are disclosed.
OBJECTIVES: I. Determine the ability of mobilization using cytarabine, etoposide, and filgrastim (G-CSF), conditioning using busulfan and etoposide, and autologous peripheral blood stem cell transplantation to generate a 2-year disease-free survival rate in at least 30% of patients with acute myeloid leukemia (AML) in second complete remission. II. Determine whether the treatment-related mortality can be limited to less than 20% in patients treated with this regimen. III. Determine whether adequate numbers of PBSC can be collected in these patients. IV. Determine the engraftment kinetics of primed PBSC obtained from these patients.

OUTLINE: Mobilization/harvest: Patients receive cytarabine IV over 2 hours every 12 hours and etoposide IV continuously on days 1-4. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning on day 14 and continuing until peripheral blood stem cells (PBSC) are harvested. When blood counts recover, PBSC are harvested and selected for CD34+ cells. Conditioning: Beginning at least 4 weeks after hospital discharge for mobilization and harvest and when blood counts recover, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Patients with documented CNS disease at first relapse receive methotrexate intrathecally at intervals of 1 week or greater before and/or after PBSC transplantation for a total of 6 doses. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 26-48 patients will be accrued within 2 years.
The invention provides a method of treating laminopathy in a subject comprising administering a therapeutically effective amount of centrobin polypeptide to the subject such that laminopathy is treated. The invention also provides a method of identifying an agent that enhances nuclear envelope integrity. The method comprises administering an agent to a cell comprising mutant centrobin, allowing the cell to replicate to form daughter cells, and observing nuclear envelope morphology within the daughter cells. In addition, the invention includes a method for diagnosing or identifying a predisposition to a laminopathy. The method comprises detecting the presence or absence of mutant centrobin in a sample, wherein the presence of mutant centrobin indicates that the subject is suffering from, or is predisposed to develop, a laminopathy. A kit for diagnosing or identifying a predisposition to a laminopathy also is provided.
Cardiac amyloidosis (CA) has diverse and deleterious effects on the conductive system. Atrial fibrillation is by far the most common electrophysiological manifestation of CA and is associated with more mortality, morbidity, and hospitalizations. While AF increases the risk of thrombosis regardless of the CHA2DS2-VASc score, the risk of thromboembolism seems to be high even in CA patients without AF. AV Nodal disease is prevalent and may precede the diagnosis of CA. The incidence of ventricular arrhythmias remains disputed, and the role of implantable cardioverter defibrillator devices in CA patients is controversial. Newer therapies targeted against specific types of CA have been developed, but their effects on conductive system disease are not well studied.
The invention provides a traditional Chinese medicine composition for treating uterine tube impotency. Suberect spatholobus stems and rhizoma sparganii jointly serve as monarch drugs straight into a blood system to specially function in breaking blood and dispersing blood stasis. Loofah sponge, beautiful sweetgum fruits, the root of red-rooted salvia and cinnamon assist the monarch drugs in warming meridians, activating blood and dredging collaterals. The monarch drugs and ministerial drugs are compatible and can function in activating blood, removing blood stasis, warming the meridians and dredging the collaterals. Spina gleditsiae, patrinia, parched white atractylodes rhizome, rhizoma cyperi, semen coicis and parched fennel function in assistance. Liquorice serves as a conductant drug. The whole formula specially functions in breaking blood, dispersing blood stasis, warming the meridians, dredging the collaterals, simultaneously regulating qi and benefiting qi, eliminating carbuncle and draining pus. Visible hard accumulation is broken, so that women suffering from the uterine tube impotency can conceive. The traditional Chinese medicine composition can remarkably treat uterine tube impotency and has no side effects.
The earlier a child initiates alcohol and other drug (AOD) use, the greater the risk of long-range problems. This association persists despite changes in national substance use rates over time, indicating its stability and viability as a target for prevention. At the same time, parent monitoring of youth behavior tends to decrease during the adolescent years, creating a source of risk for not only the early onset of AOD use but also escalation. Thus, programs are needed in parenting behaviors and family relationships that are protective in helping pre-adolescent youth to avoid initiation of AOD use and abuse. This is particularly true of children with psychiatric disorders who are at higher risk for developing AOD disorders than nonpsychiatrically disturbed children. The primary goal of this study is to test the effectiveness of a family-centered intervention to reduce the risk of AOD use among pre-adolescent children with a history of emotional/behavioral problems. In this application, the families of 80 youths aged 12-14 years, who have not yet begun AOD use but have been referred for mental health care due to psychiatric symptomatology, will be randomly assigned to receive either an individually tailored family program or standard care. The experimental intervention, which is based on the Family Check-Up model (Dishion \& Kavanagh, 2003), provides a thorough assessment of family strengths and weaknesses as they relate to future risk for AOD use as well as emotional/behavioral problems, and utilizes principles of motivational interviewing to encourage families to change. Follow-up interviews will be conducted at 6 and 12 months after baseline to assess changes in parenting, AOD use, and other risky behaviors.
The terms spina bifida and anencephaly include a range of developmental malformations that result from abnormal or incomplete closure of the neural tube. Despite advances in treatment and prenatal detection, these conditions remain as one of the most common and serious groups of birth defects. Spina bifida is associated with both increased mortality and morbidity, and anencephaly is always fatal. The occurrence of these conditions has a profound influence on affected individuals and their families and important public health implications. The etiology of NTDs has been of considerable interest for several decades. They are known to be etiologically heterogeneous and to occur in association with chromosome abnormalities, teratogenic exposures, and occasionally as part of single gene disorders. However, a specific causative agent cannot be identified in the vast majority of affected individuals. The etiology of NTDs in these "non-syndromic" patients is believed to be complex and to involve both genetic and environmental risk factors. Using a comprehensive research program, this study will evaluate the potential genetic determinants of SB and anencephaly in a large, well-characterized sample.

The family constellation used in this study consists of the proband (individual with an NTD - SB or A) and the proband's biologic parents and maternal grandparents. Blood or saliva samples are obtained from individuals and their families. Genomic DNA from all study participants is prepared from the samples, and genetic loci are evaluated. The proband, or his/her parents, complete a study questionnaire to obtain family history and epidemiologic information.
Modern experiments investigating human behaviour in emergencies are often implemented in virtual reality (VR), due to the increased experimental control and improved ethical viability over physical reality (PR). However, there remain questions regarding the validity of the results obtained from these environments, and no full validation of VR experiments has yet appeared. This study compares the results of two sets of experiments (in VR and PR paradigms) investigating behavioural responses to knife-based hostile aggressors. This study quantitatively analyses these results to ascertain whether the different paradigms generate different responses, thereby assessing the use of virtual reality as a data generating paradigm for emergencies. The results show that participants reported almost identical psychological responses. This study goes on to identify minimal differences in movement responses across a range of predictors, noting a difference in responses between genders. As a result, this study concludes that VR can produce similarly valid data as physical experiments when investigating human behaviour in hostile emergencies, and that it is therefore possible to conduct realistic experimentation through VR environments while retaining confidence in the resulting data. This has major implications for the future of this type of research, and furthermore suggests that VR experimentation should be performed for both existing and new critical infrastructure to understand human responses in hostile scenarios.
The investigators will enroll 85 adult patients, 18 years old and above, with relapsing remitting multiple sclerosis (RRMS), at the Massachusetts General Hospital MS Clinics in a pilot study of Pillsy electronic pill bottles. People with RRMS who are taking (1) fingolimod, (2) dimethyl fumarate, (3) terifluonomide, (4) diroximel fumarate, or (5) siponimod will be eligible. Patients must possess any type of smartphone capable of downloading the Pillsy application to be eligible. Per the Pillsy manufacturer, the Pillsy application is available on iPhones connected to the Apple App Store and smartphones running the Android operating system that are connected to the Google Play Store. Participants will be asked to use the Pillsy bottle for 90 days each. Participants will be randomized 1:1 to two conditions: 1) active reminders and 2) passive adherence tracking. Patients in the active reminders group will receive daily alerts through the Pillsy bottle, the Pillsy app, and their phone to remind them to take their pill. Patients in the passive adherence tracking group will not receive reminders and will instead have usual adherence monitored by the electronic pill bottle.
The invention disclosed relates to the culturing of mammalian e.g. human cells, and in particular to the culturing and expansion of substantially undifferentiated human epidermal keratinocytes exhibiting stem cell-like characteristics, and in co-culture with human dermal fibroblasts utilizing a low calcium serum free and animal by-product free medium derived from a commercially available medium. The medium consists of a commercially available basal medium, and a single fibroblast growth factor (FGF) or a mimic thereof e.g. FGF7/KGF. A method is also disclosed for treating mammalian e.g. human skin wound injuries, by applying to the wound an effective amount of substantially pure mammalian e.g. human epidermal stem cell-like keratinocytes in a substantially undifferentiated state, and optionally additionally, dermal fibroblasts e.g. human dermal fibroblasts. Both cell types can be grown separately or in a co-culture for application purposes.
Previous studies of patients with disorders of consciousness (DoC) have suggested that conscious patients may be misdiagnosed as unconscious up to 40% of the time when traditional qualitative bedside examination is used (Schnakers et al. 2009, Van Erp et al. 2015, Fins and Bernat 2018). Given the well-established prognostic relevance of early behavioral recovery of consciousness for long-term functional outcomes (Giacino and Kalmar 1997, Giacino 2004, Portaccio et al. 2018, Faugeras et al. 2018, Pincherle et al. 2019), whether or not a patient is considered to be conscious is often the primary determinant of whether life-sustaining therapy is continued and neurorehabilitation is offered. Recent advances in neuroimaging and electrophysiologic neurotechnologies, including functional magnetic resonance imaging (fMRI) and electroencephalography (EEG), have yielded novel methods to aid in detecting and predicting emergence of consciousness in patients with brain injuries. Despite these unprecedented research advances, little is known about ethical concerns surrounding these novel neurotechnologies, about the phenomenological, ontological and ethical valence of conscious states of being without behaving revealed through their lens, or about the attitudes of clinicians, researchers, patients and caregivers regarding their responsible implementation. This study aims to fill these crucial knowledge gaps and to support the development of an evidence-based strategy for ensuring responsible research and translation of novel neurotechnologies to aid in the detection of consciousness and prediction of recovery after brain injury.
Kawasaki disease, a systemic vasculitis that affects young children and can result in coronary artery aneurysms, is the leading cause of acquired heart disease among children. A hallmark of Kawasaki disease is increased blood platelet counts and platelet activation, which is associated with an increased risk of developing resistance to intravenous immunoglobulin and coronary artery aneurysms. Platelets and their releasate, including granules, microparticles, microRNAs and transcription factors, can influence innate immunity, enhance inflammation and contribute to vascular remodelling. Growing evidence indicates that platelets also interact with immune and non-immune cells to regulate inflammation. Platelets boost NLRP3 inflammasome activation and IL-1β production by human immune cells by releasing soluble mediators. Activated platelets form aggregates with leukocytes, such as monocytes and neutrophils, enhancing numerous functions of these cells and promoting thrombosis and inflammation. Leukocyte-platelet aggregates are increased in children with Kawasaki disease during the acute phase of the disease and can be used as biomarkers for disease severity. Here we review the role of platelets in Kawasaki disease and discuss progress in understanding the immune-effector role of platelets in amplifying inflammation related to Kawasaki disease vasculitis and therapeutic strategies targeting platelets or platelet-derived molecules.
A cosmetic composition containing a supercritical Lithospermum erythrorhizon extract is provided to have the effects of antioxidation, MMP-1(matrix metallo protein 1) synthesis inhibition, collagen synthesis enhancement, antiaging and antiwrinkle. A cosmetic composition for antiaging and antiwrinkle comprises 0.001-30.0 weight% of supercritical Lithospermum erythrorhizon extract as an active ingredient. The supercritical Lithospermum erythrorhizon extract is isolated by supercritical extraction using carbon dioxide at 35-100°C and the pressure of 100-500. A mixture fluid mixing with co-solvent is additionally used. The co-solvent is chloroform, ethanol, methanol, water, ethylacetate, butylacetate, hexane or diethylether. The composition is used in a form of solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, powder type foundation, emulsion type foundation, wax type foundation or spray.
A pessary (10) for treating uterine prolapse, and incontinence includes a medicated cartridge (14) that dispenses a sustained, steady dose of a drug. The drug is preferably an estrogen which, in combination with the pessary, reduces incontinence by improving the tone of genitourinary structures. The pessary (10) may be in the shape of a ring, torus or cube. It has a receptacle (16), recessed in the surface of the pessary, and open to the surrounding environment. The cartridge (14) has a shape, and size complementary to the recessed receptable (16), but the cartridge may be slightly larger than the receptacle so that the cartridge (14) may be pressed into the receptacle, and retained there for a prolonged period of time, during which the drug is released. The cartridge (14) may be selectively removed, for example by flexing the pessary or using a specialized tool, so that a new or recharged cartridge may be inserted into the receptacle. The disclosure also includes a tool with a spring biased trigger for inserting receptacles into the pessary receptacle.
The invention describes the use of the complex copper (Á4-Oxo) tetra-Á4-acetate {4-hydroxy-3,5-bis(morpholinomethyl)} tetra copper (II) (CCu-COP) for treating cervical cancer. This CCu-COP showed to be cytotoxic in 4 different cellular lines of cervical cancer, where the cellular line with the most sensitivity to the treatment of 24 hours at concentrations of from about 25 to 100 um was HeLa. The CCu-COP induces changes in the membrane of HeLa cells, where after 6 hours of treatment it was possible to detect Annexin V coupled to FITC as an indicator of the translocation of phosphatidylserine to the outer surface of the membrane. The treatment of HeLa cells with the CCu-COP possibly induced the activation of the intrinsic pathway of apoptosis, since a reduction in the procaspase-7 was observed with respect to the incubation time with CCu-COP, also showing an increase of cytochrome C in the cytoplasm, which is an indicative of permeability in the outer mitochondrial membrane. Caspase-3 could not be detected in the total extracts of HeLa treated with 74.74 um of CCu-COP, but it was detected in the cells treated with 20 um of cis-Platinum, which suggests that CCu-COP may be inducing a way of cellular death different from traditional apoptotic pathways. The cytotoxicity of the compound is related to its ability to induce peroxidation of lipids at concentrations ranging from 5 um to 20 um, which was detected by the TBARS evaluation. The CCu-COP showed a dual effect in the inhibition of lipid peroxidation induced with FeSO4, since at lower concentrations of 13.34 uM it acts synergistically with iron sulfate and increases the TBARS levels while at higher concentrations of 23.7 uM it will inhibit the peroxidation induced with FeSO4. This CCu-COP resulted to be not mutagenic in the Ames test performed in the strains TA98, TA100 and TA102 of Salmonella typhimurium at concentrations of 50, 100 and 200 uM, nor genotoxic upon evaluating the presence of micro-cores formed in per ipheral blood after the administration of a dose of the complex, where the highest concentration evaluated was of 15 mg/kg by weight in mice CD1. The delay on the tumor growth induced by 0.81 mg/kg and 8.1 mg/Kg of CCu-COP at day 16th of treatment in nude mice obeys to a reduction in the differential expression of genes related to the proliferation, metastasis and angiogenesis that this CCu-COP compound induces in tumors of cervical cancer. Finally, the histopathological study of samples of liver, spleen and kidney of mice with induced tumors that were treated with CCu-COP or cis-Platinum showed that the CCU-COP caused fewer damages to the tissue structures of the aforementioned organs, while confirming the high nephrotoxic effect of the cis-Platinum, so that it is concluded that the CCu-COP has potential as an antitumor drug against cervical cancer.
Recent progress in stem cell therapy has demonstrated the therapeutic potential of intravenous stem cell infusions for treating the life-threatening lung disease of pulmonary fibrosis (PF). However, it is confronted with limitations, such as a lack of control over cellular function and rapid clearance by the host after implantation. In this study, we developed an innovative PF therapy through tracheal administration of microfluidic-templated stem cell-laden microcapsules, which effectively reversed the progression of inflammation and fibrotic injury. Our findings highlight that hydrogel microencapsulation can enhance the persistence of donor mesenchymal stem cells (MSCs) in the host while driving MSCs to substantially augment their therapeutic functions, including immunoregulation and matrix metalloproteinase (MMP)-mediated extracellular matrix (ECM) remodeling. We revealed that microencapsulation activates the MAPK signaling pathway in MSCs to increase MMP expression, thereby degrading overexpressed collagen accumulated in fibrotic lungs. Our research demonstrates the potential of hydrogel microcapsules to enhance the therapeutic efficacy of MSCs through cell-material interactions, presenting a promising yet straightforward strategy for designing advanced stem cell therapies for fibrotic diseases.
World health statistics (2022) report that about 1.4 billion people have incurred catastrophic health expenditure (CHE), and half of its population have pushed into extreme poverty due to healthcare payments. The elderly population faces a higher risk of ill health, and seeking treatment reflects in high out-of-pocket health spending (OOPHS) that results in CHE and further impoverishment. This study aims to investigate the incidence and intensity of OOPHS, CHE, and impoverishment among the older adults in India. Data utilizes from the 75th round of the national sample survey (NSS) based on household social consumption: health (schedule 25.0), 2018. The incidence and intensity of CHE and impoverishment among older adults in India estimated by using standard measures. The older adults spend about 17.4% of household consumption expenditure on healthcare services. The poorest older adults are spending the highest share of consumption expenditure (24.8%) on healthcare among economic quantiles. Similarly, the elderly from rural (20.3%), male (18.4%), scheduled castes (21.5%), and Hinduism (17.9%) show a larger share of consumption expenditure on healthcare services. The incidence and intensity of CHE among older adults are 46.5% and 16.1% at 10% threshold level of household consumption expenditure, respectively. However, as the threshold level rises the incidence and intensity of CHE decline. The estimates of normalized poverty gap using the poverty line of Tendulkar committee as well as Rangarajan committee show that the intensity of impoverishment among older adults are 56.4% and 57.9% respectively, which is quite high. Financial protection along with vision might mitigate the risk of CHE and impoverishment among older adults in India.